Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00709215 |
Recruitment Status : Unknown
Verified January 2009 by OncoVista, Inc..
Recruitment status was: Recruiting
First Posted : July 3, 2008
Last Update Posted : January 9, 2009
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Refractory TdT-Positive Leukemia | Drug: Cordycepin plus Pentostatin | Phase 1 Phase 2 |
In the first phase the Study Objectives are to:
- Define the maximally tolerated dose (MTD) and recommended dose (RD) for administration of cordycepin as a 1-hour IV infusion, administered 1 hour following administration of an IV bolus of pentostatin, in subjects with refractory TdT-positive leukemia;
- Determine plasma ADA levels prior to pentostatin infusion and at 60 and 120 minutes after administration of pentostatin;
- Determine the single and multiple dose pharmacokinetics (PK) of cordycepin given 1 hour after a fixed dose of pentostatin;
- Assess cordycepin pharmacodynamics by measurement of blast cell apoptosis from peripheral blood smears;
- Measure and quantitate any clinical responses in refractory TdT-positive leukemia patients following cordycepin/pentostatin administration.
In the second phase, the Study Objectives are to assess the safety, PK, and clinical outcomes of cordycepin in combination with pentostatin, at the RD, in a 20 subject cohort
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 44 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase I/II Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia |
Study Start Date : | June 2008 |
Estimated Primary Completion Date : | December 2010 |
Estimated Study Completion Date : | December 2010 |

- Drug: Cordycepin plus Pentostatin
Cordycepin Plus Pentostatin on days 1, 2 and 3 of a 21 day cycle. Number of cycles until progression or unacceptable toxicity
- Establishment of the recommended dose (RD) of cordycepin, given one hour following a fixed dose of the ADA inhibitor pentostatin, in subjects with refractory TdT-positive leukemia [ Time Frame: one year ]
- Determination of the single and multiple dose pharmacokinetics of cordycepin. Measurement and quantification any any clinical responses following administration of cordycepin/pentostatin at the recomme [ Time Frame: 18 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- TdT-positive leukemia (ALL, AML, or blastic CML) that has failed at least one standard treatment regimen and for which no standard therapies are expected to result in durable remission. Leukemia is minimally defined as at least 20% blast cells present in marrow or peripheral blood. TdT must be expressed in at least 20% of blast cells present and documented either immunologically or biochemically;
- Age ≥18 years;
- Must understand and voluntarily sign informed consent;
-
Adequate non-hematologic organ system function, defined by:
- Creatinine ≤1.5 times the upper limit of normal (ULN) and/or creatinine clearance ≥60 mL/min
- AST and/or ALT ≤2.5 times upper limit of normal (ULN)
- Total bilirubin within institutional normal range
- Normal EKG and LVEF >40%, measured by EKG and MUGA scan, radionuclide ventriculogram, or echocardiogram
- Life expectancy >3 months;
- Performance status (PS) >70% Karnofsky or ECOG ≤2;
- Women of childbearing potential must have a negative serum pregnancy test within 7 days of starting study drug. A woman of child-bearing potential is a sexually mature woman who has not undergone a hysterectomy or who has not been naturally postmenopausal for at least 24 consecutive months (i.e., who has had menses at any time in the preceding 24 consecutive months);
- Male or female of child-bearing potential must agree to use adequate contraceptive methods
Exclusion Criteria:
- Failure to meet inclusion criteria;
- Uncontrolled active infection;
- Extramedullary (CNS) disease;
- Serious concomitant medical illness, such as active infection, uncontrolled congestive heart failure, or uncontrolled diabetes or other metabolic disorder, or psychiatric illness;
- Pregnancy or lactation; females of child bearing potential must use adequate contraceptive methods;
- Less than 3 weeks since prior chemotherapy, radiation therapy, or immunotherapy. However, hydroxyurea is permitted up to 24 hours before the study is initiated;
- Less than 2 months following bone marrow or peripheral blood stem cell transplantation or treatment with donor lymphocyte infusion (DLI).

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00709215
Contact: Michael Moloney, MBA, BS | 210.677.6000 ext 201 | michael.moloney@oncovista.com |
United States, Massachusetts | |
Brigham & Women's Hospital | Recruiting |
Boston, Massachusetts, United States, 02115 | |
Dana Farber Cancer Institute | Recruiting |
Boston, Massachusetts, United States, 02115 | |
Contact: Daniel J DeAngelo, MD, PhD. 617-632-2645 Daniel_Deangelo@dfci.harvard.edu | |
Principal Investigator: Daneil J DeAngelo, MD, PhD. | |
Sub-Investigator: Richard Stone, MD | |
Sub-Investigator: L. Andres Sirulnik, MD | |
Sub-Investigator: Martha Wadleigh, MD | |
Sub-Investigator: Gregory Abel, MD, MPH | |
Sub-Investigator: Susan L Buchanan, PA | |
Sub-Investigator: Adriana Penicaud, PA | |
Sub-Investigator: Ilene Galinsky, APRN | |
Sub-Investigator: Eyal Attar, MD | |
Sub-Investigator: Philip Amrein, MD | |
Sub-Investigator: Karen Kuhn Ballen, MD | |
United States, Texas | |
Cancer Therapy Reasearch Center at UTHSCA | Recruiting |
San Antonio, Texas, United States, 78229 | |
Contact: Swaminathan Padmanabhan, MD 210-450-5094 PadmanabhanS@uthscsa.edu | |
Sub-Investigator: Monica Mita, MD | |
Principal Investigator: Alain Mita, MD |
Principal Investigator: | Swaminathan Padmanabhan, MD | Cancer Therapy Research Center at UTHSCSA | |
Principal Investigator: | Daneil J DeAngelo, MD, PhD. | Dana Farber Cancr Institute |
Responsible Party: | Michael Moloney, Director - Program Management, OncoVista, Inc. |
ClinicalTrials.gov Identifier: | NCT00709215 |
Other Study ID Numbers: |
OV06-001 |
First Posted: | July 3, 2008 Key Record Dates |
Last Update Posted: | January 9, 2009 |
Last Verified: | January 2009 |
refractory TdT-positive leukemia ALL AML blastic CML |
Leukemia Neoplasms by Histologic Type Neoplasms Cordycepin Pentostatin Antineoplastic Agents |
Adenosine Deaminase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antifungal Agents Anti-Infective Agents |